CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 16 enrolled
Drug / intervention
IV Acetaminophen +1 moredrug
Likely dose
IV Acetaminophen 1000mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01783236
NCT01783236Phase 4Completed

A Double-blind, Randomized, Placebo-controlled Study to Compare the Effectiveness of IV Acetaminophen Administered Intra-operatively in Reducing the Use of Opiates to Treat Post-operative Pain

Weill Medical College of Cornell University·interventional·Posted Feb 4, 2013·Updated May 11, 2017

In Brief

A Phase 4 clinical trial evaluating IV Acetaminophen and Saline Placebo for Lung Tumor. Completed, enrolled 16 participants across 1 site.

Detailed Summary

We will study the efficacy of FDA approved intravenous (IV) acetaminophen ("Ofirmev", © 2011 Cadence Pharmaceuticals, Inc.) in reducing opioid consumption after minimally invasive thoracic surgery in a double blind randomized trial. This drug has been shown in Europe to reduce the need for patient controlled analgesia and the total dose of opioids, which have serious side effects in thoracic surgery patients. We will compare the use of IV patient-controlled morphine (PCA) in two groups of subjects in treating postoperative pain. We will determine if IV acetaminophen reduces post-operative morphine requirements (primary end point). We will also assess subject pain scores and post-operative complications associated with pain management as secondary end points. Our hypothesis is that the study arm receiving intravenous acetaminophen will have lower total morphine consumptions compared to the placebo group.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Tumor
CountriesUnited States
CollaboratorsMallinckrodt

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 4, 2013
Enrollment StartJun 1, 2013
Primary CompletionFeb 1, 2015
Study CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 13.4 years ago

Interventions

IV Acetaminophendrug

1000mg IV Ofirmev given every six hours for a total of four doses.

Saline Placebodrug

Normal saline placebo given every six hours for a total of four doses if randomized to the placebo arm.